Lexeo Therapeutics Inc (LXEO) Q4 2025 Earnings Call Transcript

Why It Matters

The strong revenue growth and advancing ZANZALUTINIB pipeline position Exelixis for multi‑franchise expansion, reinforcing its leadership in solid‑tumor oncology and supporting shareholder value.

Key Takeaways

• US cabozantinib revenue $2.12B, up 17% YoY
• Global cabozantinib sales $2.89B, strong international demand
• ZANZALUTINIB NDA accepted, PDUFA decision by December
• CABOMETYX market share rose to 46%, TRx up 15%
• Cash $1.66B supports pipeline and share buybacks

Pulse Analysis

Exelixis’ 2025 financial results underscore the durability of its cabozantinib franchise, which now commands over $2 billion in U.S. sales and nearly $3 billion worldwide. The drug’s leadership in renal cell carcinoma and its recent approval for neuroendocrine tumors have driven a 17% revenue lift, while a 15% prescription‑volume growth outpaced the broader oral TKI market. This momentum not only bolsters earnings but also strengthens the company’s negotiating leverage with payers, as gross‑to‑net ratios are expected to rise modestly to 31‑32% in 2026.

Beyond the flagship product, Exelixis is positioning ZANZALUTINIB as its next oncology franchise. The FDA’s acceptance of the new‑drug application for a cabozantinib‑atezolizumab combination in third‑line colorectal cancer, coupled with a 20% overall‑survival reduction reported in the STELLAR‑303 trial, signals a potentially transformative therapy. With seven pivotal trials underway and growing interest from clinical collaborators, ZANZALUTINIB could expand the company’s reach into the lucrative colorectal market, complementing its existing GU and GI focus.

Financially, the firm’s balance sheet remains robust, featuring $1.66 billion in cash and marketable securities and a $954 million share‑repurchase program that retired roughly 24 million shares. This disciplined capital allocation supports both pipeline acceleration and shareholder returns. Looking ahead, the expanded gastrointestinal sales force and anticipated regulatory milestones set the stage for sustained growth in 2026, as Exelixis aims to translate its franchise‑centric strategy into broader market share and long‑term value creation.